Ted W. Love - 17 Sep 2026 Form 3 Insider Report for LISATA THERAPEUTICS, INC. (LSTA)

Reporting relationship: Director
Issuer ticker: LSTA
Reported as of: 17 Sep 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 28 Sep 2026, 21:30:38 UTC
Prior SEC filing: 02 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ James Nisco, Attorney-in-Fact for Ted W. Love

Key filing fact

Ted W. Love filed Form 3 for LISATA THERAPEUTICS, INC. (LSTA) on 28 Sep 2026.

Key facts

This page summarizes Ted W. Love's Form 3 filing for LISATA THERAPEUTICS, INC. (LSTA).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Sep 2026, 21:30.

Change

Previous filing in this sequence was filed on 02 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001188919 Primary reporting owner

LOVE TED W

Relationship: Director
Address: C/O LISATA THERAPEUTICS, INC., P.O. BOX 173, LIBERTY CORNER
Signature: /s/ James Nisco, Attorney-in-Fact for Ted W. Love
Signature date: 28 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LSTA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 19,260
Date: 17 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LSTA holding Derivative

Series C Non-Voting Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,270,316
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported shares of Common Stock and shares of Common Stock underlying shares of Series C Non-Voting Convertible Preferred Stock represent shares received in exchange for 2,354,899 shares of common stock of Marea Therapeutics, Inc. ("Marea") in connection with the Issuer's merger (the "Merger") with Marea pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 17, 2026, by and among the Issuer, Marea, Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Marea's

Footnote F2

(continued from Footnote 1) common stock was cancelled and converted into the right to receive 0.9723 shares of Common Stock or, in lieu thereof, 0.0009723 shares of Series C Non-Voting Convertible Preferred Stock (representing 0.9723 shares of Common Stock on an as-converted basis). A portion of the reported shares of Common Stock and Series C Non-Voting Convertible Preferred Stock are subject to an Issuer right of repurchase that lapses in accordance with time- or milestone-based vesting conditions set forth in the applicable stock purchase agreements.

Footnote F3

Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon the approval of such conversion by the Issuer's stockholders in accordance with the rules of the Nasdaq Stock Market LLC, subject to a beneficial ownership limitation to be established by the holder of between 4.9% and 19.99% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.

SEC remarks

Power of Attorney attached as Exhibit 24.